Findings from an ad hoc analysis evaluating changes in BVI in those with at least one G551D mutation before and after 2012 FDA approval of ivacaftor.

<p>Panel a.) shows the number of individuals with the G551D mutation by age, before (light green) and after 2012 (dark green), b.) shows estimated between-visit interval across the lifespan before and after 2012 FDA approval of ivacaftor. Color shaded areas indicate 95% confidence bounds. The gray shaded area indicates the current CF Foundation-recommended between-visit interval of 90 days for reference.</p> <p>(PDF)</p>